Cushing’s syndrome (CS) is associated with multisystemic complications; the hematological system is not spared. Alteration in hemostatic parameters and in vivo endothelial dysfunction lead to increased thrombotic events. Arterial and venous thrombotic events carry significant morbidity and mortality. Death from cardiovascular and pulmonary embolism account for more than 50% of mortality. Surgery is a critical period; close to 50% of events occur in the 1–2 months after intervention. The evaluation and risk stratification of patients with CS is key to prevent events, balancing the risk-benefit of anticoagulation in this population. This current review will focus on up-to-date data on epidemiology, pathophysiology and management of hypercoagulability in CS.

库欣综合征 (CS) 与多系统并发症有关；血液系统也不能幸免。止血参数和体内内皮功能障碍的改变导致血栓事件增加。动脉和静脉血栓事件具有显着的发病率和死亡率。心血管和肺栓塞导致的死亡占死亡人数的 50% 以上。手术是关键时期；接近 50% 的事件发生在干预后的 1-2 个月内。CS 患者的评估和风险分层是预防事件的关键，平衡该人群中抗凝治疗的风险-收益。本综述将重点关注 CS 中高凝状态的流行病学、病理生理学和管理的最新数据。